Since CCL2 mediated cell signaling pathway activation and PARP1 inhibition are negatively correlated in breast cancer cells, we compared whole transcriptome profiles of MB-231 with rhCCL2 or PJ34 treatment. The gene discussed is CCL2; the disease is breast cancer.